Literature DB >> 30042094

Disparities in survival by insurance status in follicular lymphoma.

Jordan S Goldstein1, Loretta J Nastoupil2, Xuesong Han3, Ahmedin Jemal3, Elizabeth Ward3, Christopher R Flowers1.   

Abstract

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and most common indolent non-Hodgkin lymphoma. Lower socioeconomic status is associated with poor outcomes in FL, suggesting that access to care is an important prognostic factor; however, the association between insurance status and FL survival has not been sufficiently examined. The National Cancer Database, a nationwide cancer registry, was used to evaluate 43 648 patients with FL diagnosed between 2004 and 2014. All analyses were performed on 2 cohorts segmented at age 65 years to account for changes in insurance status with Medicare eligibility. Cox proportional hazard models calculated hazard ratios (HRs) with confidence intervals (CIs) for the association between insurance status and overall survival (OS) controlling for the available sociodemographic and prognostic factors. Kaplan-Meier curves display outcomes by insurance status for patients covered by private insurance, no insurance, Medicaid, or Medicare. When compared with patients younger than age 65 years with private insurance, patients younger than age 65 years with no insurance (HR, 1.96; 95% CI, 1.69-2.28), with Medicaid (HR, 1.82; 95% CI, 1.57-2.12), and with Medicare (HR, 1.96; 95% CI, 1.71-2.24) had significantly worse OS after adjusting for sociodemographic and prognostic factors. Compared with patients age 65 years or older with private insurance, those with Medicare only (HR, 1.28; 95% CI, 1.17-1.4) had significantly worse OS. For adults with FL, expanding access to care through insurance has the potential to improve outcomes.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30042094      PMCID: PMC6137560          DOI: 10.1182/blood-2018-03-839035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Access To Care And Affordability Have Improved Following Affordable Care Act Implementation; Problems Remain.

Authors:  Adele Shartzer; Sharon K Long; Nathaniel Anderson
Journal:  Health Aff (Millwood)       Date:  2015-12-16       Impact factor: 6.301

2.  Association Between the Affordable Care Act Dependent Coverage Expansion and Cervical Cancer Stage and Treatment in Young Women.

Authors:  Anthony S Robbins; Xuesong Han; Elizabeth M Ward; Edgar P Simard; Zhiyuan Zheng; Ahmedin Jemal
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

3.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

4.  Why Health Insurance Matters-and Why Research Evidence Should Too.

Authors:  Benjamin D Sommers
Journal:  Acad Med       Date:  2017-09       Impact factor: 6.893

5.  Health Insurance Coverage and Health - What the Recent Evidence Tells Us.

Authors:  Benjamin D Sommers; Atul A Gawande; Katherine Baicker
Journal:  N Engl J Med       Date:  2017-06-21       Impact factor: 91.245

6.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

7.  Impact of Health Insurance Expansion on the Treatment of Colorectal Cancer.

Authors:  Andrew P Loehrer; Zirui Song; Alex B Haynes; David C Chang; Matthew M Hutter; John T Mullen
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

8.  Improved survival of follicular lymphoma patients in the United States.

Authors:  Wade T Swenson; James E Wooldridge; Charles F Lynch; Valerie L Forman-Hoffman; Elizabeth Chrischilles; Brian K Link
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

9.  How I treat indolent lymphoma.

Authors:  John G Gribben
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

10.  Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.

Authors:  Philippe Solal-Céligny; Monica Bellei; Luigi Marcheselli; Emanuela Anna Pesce; Stefano Pileri; Peter McLaughlin; Stefano Luminari; Barbara Pro; Silvia Montoto; Andrés J M Ferreri; Eric Deconinck; Noël Milpied; Leo I Gordon; Massimo Federico
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

View more
  8 in total

1.  Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.

Authors:  Andrew J Ritter; Jordan S Goldstein; Amy A Ayers; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-01-11

2.  Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Authors:  Thomas A Ollila; John L Reagan; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-07-09

3.  Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.

Authors:  Amy A Ayers; Lin Lyu; Kaylin Dance; Kevin C Ward; Christopher R Flowers; Jean L Koff; Lauren E McCullough
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-26

4.  Perceptions of clinical care and research among African-American patients with lymphoma.

Authors:  Kaylin V Dance; Conner B Imbody; Lillian Chen; Lorna McNeill; Jackelyn B Payne; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2021-02-28

Review 5.  Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.

Authors:  Stergios Intzes; Marianthi Symeonidou; Konstantinos Zagoridis; Zoe Bezirgianidou; Georgios Vrachiolias; Athina Spanoudaki; Emmanouil Spanoudakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-01-01       Impact factor: 2.576

6.  Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China.

Authors:  Jing Wu; Chengyu Liu; Fengmei Wang
Journal:  Front Public Health       Date:  2021-11-05

7.  Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019.

Authors:  Weiping Liu; Jiangmei Liu; Yuqin Song; Xiaopei Wang; Lan Mi; Cai Cai; Donglu Zhao; Lijun Wang; Jun Ma; Jun Zhu
Journal:  Aging (Albany NY)       Date:  2022-04-10       Impact factor: 5.682

Review 8.  Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

Authors:  Vishwanath Sathyanarayanan; Christopher R Flowers; Swaminathan P Iyer
Journal:  JCO Glob Oncol       Date:  2020-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.